Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5702221 | 1.00 | ALDH1A1 (0.62) | ALDH1A1HTTMMP2GAAHPGD | |
| SCHEMBL5702094 | 1.00 | ALDH1A1 (0.62) | ALDH1A1HTTMMP2GAAHPGD | |
| SCHEMBL696506 | 0.92 | ALDH1A1 (0.68) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL2636629 | 0.92 | ALDH1A1 (0.68) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL696505 | 0.92 | ALDH1A1 (0.68) | ALDH1A1HTTGAAHPGDPOLB | |
| Hydrochloric Acid SCHEMBL4077466 | 0.91 | ALDH1A1 (0.67) | ALDH1A1HTTGAAHPGDPOLB | |
| Hydrochloric Acid SCHEMBL4077465 | 0.91 | ALDH1A1 (0.67) | ALDH1A1HTTGAAHPGDPOLB | |
| Water SCHEMBL5497101 | 0.91 | ALDH1A1 (0.67) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL6302459 | 0.88 | ALDH1A1 (0.64) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL16635434 | 0.86 | ALDH1A1 (0.59) | ALDH1A1HTTGAALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1193253-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AZETIDINE-2-CARBOXYLIC ACIDS | KANEKA CORP (JP) | 2008-06-25 | — | — | EP | disclosed |
| EP-1927588-A2 | Process for producing optically active azetidine-2-carboxylic acids | KANEKA CORPORATION (JP) | 2008-06-04 | — | — | EP | disclosed |
| US-7262308-B2 | Process for producing optically active azetidine-2-carboxylic acids | KANEKA CORPORATION (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-0974670-B1 | Process for producing optically active N-substituted azetidine-2-carboxylic acid compound | SUMITOMO CHEMICAL CO (JP) | 2006-09-13 | — | — | EP | disclosed |
| US-20050043547-A1 | Process for producing optically active azetidine-2-carboxylic acids | HONDA TATSUYA (JP) | 2005-02-24 | — | — | US | disclosed |
| US-6838567-B1 | Process for producing optically active azetidine-2-carboxylic acids | KANEKA CORPORATION (JP) | 2005-01-04 | — | — | US | disclosed |
| US-20040171849-A1 | Process for producing optically active azetidine-2-carboxylic acid | KANEKA CORPORATION (JP) | 2004-09-02 | — | — | US | disclosed |
| EP-1415985-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AZETIDINE-2-CARBOXYLIC ACID | KANEKA CORPORATION (JP) | 2004-05-06 | — | — | EP | disclosed |
| CN-1125064-C | 3-pyridyl enantiomers and their use as analgesics | ABBOTT LAB (US) | 2003-10-22 | — | — | CN | disclosed |
| EP-0992491-B1 | PROCESSES FOR PRODUCING AZETIDINE-2-CARBOXYLIC ACID AND INTERMEDIATES THEREOF | KANEKA CORP (JP) | 2003-03-05 | — | — | EP | disclosed |
| EP-1047690-A1 | HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 2000-11-02 | — | — | EP | disclosed |
| US-6133253-A | NEURONAL CELL DEATH PREVENTORS AND ANTI-INFLAMMATORIES | ABBOTT LABORATORIES (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0992491-A1 | PROCESSES FOR PRODUCING AZETIDINE-2-CARBOXYLIC ACID AND INTERMEDIATES THEREOF | KANEKA CORPORATION (JP) | 2000-04-12 | — | — | EP | disclosed |
| CN-1245496-A | 3-pyridyl enantiomers and their use as analgesics | ABBOTT LAB (US) | 2000-02-23 | — | — | CN | disclosed |
| EP-0974670-A2 | Process for producing optically active N-substituted azetidine-2-carboxylic acid compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-01-26 | — | — | EP | disclosed |
| EP-0950057-A1 | 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS | Abbott Laboratories (US) | 1999-10-20 | — | — | EP | disclosed |
| US-5948793-A | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release | ABBOTT LABORATORIES (US) | 1999-09-07 | — | — | US | disclosed |
| WO-1999032480-A1 | HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 1999-07-01 | — | — | WO | disclosed |
| US-5914328-A | CONTROL DOPAMINE RELEASE, ACTIVATE CHOLINERGIC CHANNELS | ABBOTT LABORATORIES (US) | 1999-06-22 | — | — | US | disclosed |
| WO-1998025920-A1 | 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS | ABBOTT LABORATORIES (US) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171849-A1 | Process for producing optically active azetidine-2-carboxylic acid | HBB, ADCY2, ADCY9 | ALDH1A1 587/4885HTT 949/4885MMP2 1999/4885 |
| US-20050043547-A1 | Process for producing optically active azetidine-2-carboxylic acids | AZI2, ALAD, HBB | ALDH1A1 1133/4885HTT 644/4885MMP2 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.